



Chengdu KaiJie Biopharm Co., Ltd.

Segment 1, Industrial Road, Dayi county, Chengdu, Sichuan, P. R. China, 611330
Tel: 86-28-88208155, Fax: 86-28-88203632 WEB: www.kjpep.com

About Author

Chengdu Kaijie Biopharm Co, Ltd. (KJBP) is one of leading peptide manufacturers in Asia. With its highest capacity of production in China and the outstanding quality of peptide products, Kaijie holds a unique position.

Exenatide

H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂

www.kjpep.com
sales@kjpep.com

1. US Trade Name: Byetta

2. How Supplied

2.1. Byetta :

Subcutaneous Solution: 250 MCG/ML

3. Adult Dosing

Diabetes mellitus type 2, In patients taking metformin, a sulfonylurea, a thiazolidinedione, a combination of metformin and a sulfonylurea or a thiazolidinedione, but have not achieved adequate glycemic control; Adjunct: initial, 5 mcg SUBQ twice daily; maintenance, 10 mcg SUBQ twice daily after 1 month of therapy

4. Pediatric Dosing

Safety and effectiveness have not been established in pediatric patients

5. Dose Adjustments

Renal impairment: end-stage renal disease receiving dialysis or severe renal impairment (creatinine clearance less than 30 milliliters/minute), not recommended .

6. Mechanism of Action

Exenatide is an incretin mimetic agent that mimics the enhancement of glucose-dependent insulin secretion and several other antihyperglycemic actions of incretins. Incretins, such as glucagon-like peptide-1 (GLP-1), enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following release into circulation from the gut.



Chengdu KaiJie Biopharm Co., Ltd.

Segment 1, Industrial Road, Dayi county, Chengdu, Sichuan, P. R. China, 611330
Tel: 86-28-88208155, Fax: 86-28-88203632 WEB: www.kjpep.com

7. Pharmacokinetics

7.1 Absorption

Subcutaneous: time to peak plasma concentration, 2.1 h

7.2. Distribution

Vd: 28.3 L

7.3. Excretion

Renal: predominantly glomerular filtration with subsequent proteolytic degradation

7.4. Elimination Half Life

Adults: 2.4 h

8. Adverse Effects

Endocrine metabolic: Hypoglycemia (4.5% to 35.7%)

Gastrointestinal: Diarrhea (13%), Indigestion (6%), Nausea (44%), Vomiting (13%)

Immunologic: Antibody development (6% to 9%)

Neurologic: Dizziness (9%), Feeling nervous (9%), Headache (9%)